Documents

Gillessen, S.[a b] , Bossi, A.[c] , Davis, I.D.[d] , de Bono, J.[e f] , Fizazi, K.[g] , James, N.D.[e] , Mottet, N.[h] , Shore, N.[i j] , Small, E.[k] , Smith, M.[l] , Sweeney, C.J.[m] , Tombal, B.[n] , Antonarakis, E.S.[o] , Aparicio, A.M.[p] , Armstrong, A.J.[q] , Attard, G.[r] , Beer, T.M.[s] , Beltran, H.[t] , Bjartell, A.[u] , Blanchard, P.[v] , Briganti, A.[w] , Bristow, R.G.[x y] , Bulbul, M.[z] , Caffo, O.[aa] , Castellano, D.[ab] , Castro, E.[ac] , Cheng, H.H.[ad] , Chi, K.N.[ae] , Chowdhury, S.[af] , Clarke, C.S.[ag] , Clarke, N.[ah] , Daugaard, G.[ai] , De Santis, M.[aj ak] , Duran, I.[al] , Eeles, R.[am] , Efstathiou, E.[an] , Efstathiou, J.[ao] , Ekeke, O.N.[ap] , Evans, C.P.[aq] , Fanti, S.[ar] , Feng, F.Y.[as] , Fonteyne, V.[at] , Fossati, N.[au] , Frydenberg, M.[av] , George, D.[aw] , Gleave, M.[ax] , Gravis, G.[ay] , Halabi, S.[az] , Heinrich, D.[ba] , Herrmann, K.[bb] , Higano, C.[bc] , Hofman, M.S.[bd] , Horvath, L.G.[be bf bg] , Hussain, M.[bh] , Jereczek-Fossa, B.A.[bi bj] , Jones, R.[bk] , Kanesvaran, R.[bl] , Kellokumpu-Lehtinen, P.-L.[bm bn] , Khauli, R.B.[bo] , Klotz, L.[bp] , Kramer, G.[bq] , Leibowitz, R.[br bs] , Logothetis, C.[p bt] , Mahal, B.[bu] , Maluf, F.[bv bw] , Mateo, J.[bx] , Matheson, D.[by] , Mehra, N.[bz] , Merseburger, A.[ca] , Morgans, A.K.[t] , Morris, M.J.[cb] , Mrabti, H.[cc] , Mukherji, D.[cd] , Murphy, D.G.[ce cf] , Murthy, V.[cg] , Nguyen, P.L.[ch] , Oh, W.K.[ci] , Ost, P.[cj ck] , O'Sullivan, J.M.[cl] , Padhani, A.R.[cm] , Pezaro, C.J.[cn] , Poon, D.M.C.[co cp] , Pritchard, C.C.[cq] , Rabah, D.M.[cr cs] , Rathkopf, D.[ct] , Reiter, R.E.[cu] , Rubin, M.A.[cv] , Ryan, C.J.[cw] , Saad, F.[cx] , Sade, J.P.[cy] , Sartor, O.[cz] , Scher, H.I.[ct da] , Sharifi, N.[db dc] , Skoneczna, I.[dd] , Soule, H.[de] , Spratt, D.E.[df] , Srinivas, S.[dg] , Sternberg, C.N.[dh] , Steuber, T.[di dj] , Suzuki, H.[dk] , Sydes, M.R.[dl] , Taplin, M.-E.[dm] , Tilki, D.[di dj dn] , Türkeri, L.[do] , Turco, F.[a] , Uemura, H.[dp] , Uemura, H.[dq] , Ürün, Y.[dr ds] , Vale, C.L.[dt] , van Oort, I.[du] , Vapiwala, N.[dv] , Walz, J.[dw] , Yamoah, K.[dx] , Ye, D.[dy dz] , Yu, E.Y.[ea] , Zapatero, A.[eb] , Zilli, T.[ec ed] , Omlin, A.[ee]

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

(2023) *European Journal of Cancer*, 185, pp. 178-215. Cited 45 times.

DOI: 10.1016/j.ejca.2023.02.018

[a] Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
[b] Università della Svizzera Italiana, Lugano, Switzerland
[c] Genitourinary Oncology, Prostate Brachytherapy Unit, Gustave Roussy, Paris, France
[d] Monash University and Eastern HealthVIC, Australia
[e] The Institute of Cancer Research, London, United Kingdom
[f] Royal Marsden Hospital, London, United Kingdom
[g] Institut Gustave Roussy, University of Paris Saclay, Villejuif, France
[h] University Jean Monnet, St Etienne, France
[i] Medical Director, Carolina Urologic Research Center, Myrtle Beach, SC, United States
[j] CMO, Urology/Surgical Oncology, GenesisCare, Myrtle Beach, SC, United States
[k] UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States
[l] Massachusetts General Hospital Cancer Center, Boston, MA, United States
[m] South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia
[n] Cliniques universitaires Saint Luc, Brussels, Belgium
[o] University of Minnesota Masonic Cancer Center, Minneapolis, MN, United States
[p] Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
[q] Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, United States
[r] University College London Cancer Institute, London, United Kingdom
[s] Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States
[t] Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
[u] Department of Urology, Skåne University Hospital, Malmö, Sweden
[v] Gustave Roussy, Département de Radiothérapie, Université Paris-Saclay, Oncostat, Inserm U-1018, F-94805, Villejuif, France
[w] Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
[x] Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
[y] Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, United Kingdom
[z] Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
[aa] Department of Medical Oncology, Santa Chiara Hospital, Trento, 38122, Italy
[ab] Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
[ac] Institute of Biomedical Research in Málaga (IBIMA), Málaga, Spain
[ad] University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, United States
[ae] BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
[af] Guys and St Thomas's NHS Foundation Trust, London, United Kingdom
[ag] Research Department of Primary Care & Population Health, Royal Free Campus, University College London, London, United Kingdom
[ah] The Christie and Salford Royal Hospitals, Manchester, United Kingdom
[ai] Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
[aj] Department of Urology, Charité Universitätsmedizin, Berlin, Germany
[ak] Department of Urology, Medical University of Vienna, Austria
[al] Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Cantabria, Santander, Spain
[am] The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom
[an] Houston Methodist Cancer Center, Houston, TX, United States
[ao] Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States
[ap] Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria
[aq] University of California Davis School of Medicine, Sacramento, CA, United States
[ar] IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
[as] University of California, San Francisco, San Francisco, CA, United States
[at] Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium
[au] Department of Urology, Ospedale Regionale di Lugano, Civico USI – Università della Svizzera Italiana, Lugano, Switzerland
[av] Department of Surgery, Prostate Cancer Research Program, Department of Anatomy & Developmental Biology, Faculty Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia
[aw] Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, United States
[ax] Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada
[ay] Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France
[az] Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States
[ba] Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway
[bb] Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
[bc] University of British Columbia, Vancouver, BC, Canada
[bd] Prostate Cancer Theranostics and Imaging Centre of Excellence, Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
[be] Chris O'Brien Lifehouse, Camperdown, NSW, Australia
[bf] Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia
[bg] The University of Sydney, Sydney, NSW, Australia
[bh] Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States
[bi] Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
[bj] Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy
[bk] School of Cancer Sciences, University of Glasgow, United Kingdom
[bl] Division of Medical Oncology, National Cancer Centre, Singapore
[bm] Faculty of Medicine and Health Technology, Tampere University and Tampere Cancer Center, Tampere, Finland
[bn] Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland

[bo] Division of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon
[bp] Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
[bq] Department of Urology, Medical University of Vienna, Vienna, Austria
[br] Oncology Institute, Shamir Medical Center, Be'er Ya'akov, Israel
[bs] Faculty of Medicine, Tel-Aviv University, Israel
[bt] University of Athens Alexandra Hospital, Athens, Greece
[bu] Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, United States
[bv] Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brazil
[bw] Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
[bx] Department of Medical Oncology and Prostate Cancer Translational Research Group. Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain
[by] Faculty of Education, Health and Wellbeing, Walsall Campus, Walsall, United Kingdom
[bz] Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
[ca] Department of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany
[cb] Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States
[cc] National Institute of Oncology, Mohamed V University, Rabat, Morocco
[cd] Clemenceau Medical Center Dubai, United Arab Emirates, Faculty of Medicine, American University of Beirut, Lebanon
[ce] Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia
[cf] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
[cg] Tata Memorial Centre, Mumbai, India
[ch] Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
[ci] Chief, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, United States
[cj] Department of Human Structure and Repair, Ghent University, Ghent, Belgium
[ck] Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium, Ghent University, Ghent, Belgium
[cl] Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, United Kingdom
[cm] Mount Vernon Cancer Centre and Institute of Cancer Research, London, United Kingdom
[cn] Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
[co] Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong
[cp] The Chinese University of Hong Kong, Shatin, Hong Kong
[cq] Department of Laboratory Medicine and Pathology, University of Washington, Seattle, United States
[cr] Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia
[cs] Department of Urology, KFSHRC Riyadh, Saudi Arabia
[ct] Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
[cu] University of California Los Angeles, Los Angeles, CA, United States
[cv] Bern Center for Precision Medicine and Department for Biomedical Research, Bern, Switzerland
[cw] Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States
[cx] Centre Hospitalier de Université de Montréal, Montreal, Canada
[cy] Instituto Alexander Fleming, Buenos Aires, Argentina
[cz] Tulane Cancer Center, New Orleans, LA, United States
[da] Department of Medicine, Weill Cornell Medical College, New York, NY, United States
[db] Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States
[dc] Department of Cancer Biology, GU Malignancies Research Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH, United States
[dd] Rafal Masztak Grochowski Hospital, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland
[de] Prostate Cancer Foundation, Santa Monica, CA, United States
[df] University Hospitals Seidman Cancer Center, Cleveland, OH, United States
[dg] Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, United States
[dh] Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, United States
[di] Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
[dj] Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
[dk] Toho University Sakura Medical Center, Chiba, Japan
[dl] MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom
[dm] Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
[dn] Department of Urology, Koc University Hospital, Istanbul, Turkey
[do] Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey
[dp] Yokohama City University Medical Center, Yokohama, Japan
[dq] Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan
[dr] Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
[ds] Ankara University Cancer Research Institute, Ankara, Turkey
[dt] University College London, MRC Clinical Trials Unit at UCL, London, United Kingdom
[du] Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands
[dv] Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States
[dw] Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France
[dx] Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, United States
[dy] Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
[dz] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
[ea] Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Center, G4–830, Seattle, WA, United States
[eb] Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain
[ec] Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
[ed] Faculty of Medicine, University of Geneva, Geneva, Switzerland
[ee] Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Switzerland

Abstract
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence. Objective: To present the voting results of the APCCC 2022. Design, setting, and participants: The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions. Outcome measurements and statistical analysis: The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions. Results and limitations: The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer. Conclusions: These voting results in four specific areas from a panel of experts in advanced prostate cancer can help clinicians and patients navigate controversial areas of management for which high-level evidence is scant or conflicting and can help research funders and policy makers identify information gaps and consider what areas to explore further. However, diagnostic and treatment decisions always have to be individualised based on patient characteristics, including the extent and location of disease, prior treatment(s), co-morbidities, patient preferences, and treatment recommendations and should also incorporate current and emerging clinical evidence and logistic and economic factors. Enrolment in clinical trials is strongly encouraged. Importantly, APCCC 2022 once again identified important gaps where there is non-consensus and that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with healthcare providers worldwide. At each APCCC, an expert panel votes on pre-defined questions that target the most clinically relevant areas of advanced prostate cancer treatment for which there are gaps in knowledge. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients and their relatives as part of shared and multidisciplinary decision-making. This report focuses on the advanced setting, covering metastatic hormone-sensitive prostate cancer and both non-metastatic and metastatic castration-resistant prostate cancer. Twitter summary: Report of the results of APCCC 2022 for the following topics: mHSPC, nmCRPC, mCRPC, and oligometastatic prostate cancer. Take-home message: At APCCC 2022, clinically important questions in the management of advanced prostate cancer management were identified and discussed, and experts voted on pre-defined consensus questions. The report of the results for metastatic and/or castration-resistant prostate cancer is summarised here. © 2023 The Authors

Author Keywords
Androgen receptor pathway inhibitors (ARPI); Chemotherapy; Hormonal treatment; Metastatic castration-resistant prostate cancer (mCRPC) and oligometastatic and oligoprogressive prostate

cancer; Metastatic hormone-sensitive prostate cancer (mHSPC); Next-generation imaging; Non metastatic castration-resistant prostate cancer (nmCRPC); PSMA PET-imaging; Systemic therapy

Index Keywords
androgen, antineoplastic hormone agonists and antagonists, docetaxel, nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor, vipivotide tetraxetan lutetium lu 177, hormone; advanced cancer, biochemical recurrence, cancer hormone therapy, cancer patient, cancer prognosis, clinical feature, Conference Paper, consensus development, Delphi study, frailty, genetic profile, human, local therapy, medical expert, metastatic castration resistant prostate cancer, metastatic castration sensitive prostate cancer, monitoring, multiple cancer, outcome assessment, second cancer, side effect, castration resistant prostate cancer, coronavirus disease 2019, diagnostic imaging, male, meta analysis, pathology; COVID-19, Diagnostic Imaging, Hormones, Humans, Male, Prostatic Neoplasms, Castration-Resistant

Correspondence Address
Gillessen S.; Oncology Institute of Southern SwitzerlandSwitzerland; email: silke.gillessen@eoc.ch

Publisher: Elsevier Ltd

ISSN: 09598049
CODEN: EJCAE
PubMed ID: 37003085
Language of Original Document: English
Abbreviated Source Title: Eur. J. Cancer
2-s2.0-85151286476
Document Type: Conference Paper
Publication Stage: Final
Source: Scopus

ELSEVIER Copyright © 2024 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V. RELX Group™